3088 studies found for:    "Endocrine Gland Neoplasms"
Show Display Options
Rank Status Study
21 Terminated Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
Conditions: Colon Tumors;   Rectum Tumors;   Appendix Tumors;   Peritoneum Tumors;   Endocrine Tumors
Intervention: Drug: Oxaliplatin and irinotecan
22 Recruiting Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Conditions: Acromegaly;   Gigantism;   Familial Isolated Pituitary Adenoma;   FIPA;   Pituitary Adenoma Predisposition;   PAP
Intervention:
23 Completed Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Conditions: Carcinoma;   Carcinoma, Renal Cell;   Neuroendocrine Tumors;   Carcinoid Tumor;   Pancreatic Islet Cell Tumors
Intervention: Other: Blood sampling by vena punction.
24 Recruiting Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Conditions: Neuroendocrine Tumors;   Hepatic Metastases;   Metastases
Interventions: Drug: Everolimus;   Device: embolization;   Drug: Doxorubicin
25 Not yet recruiting PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation
Condition: Neuroendocrine Tumors
Intervention: Procedure: 68Ga-DOTATOC PET-CT Imaging
26 Terminated
Has Results
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
Condition: Pancreatic Cancer
Interventions: Drug: Avastin;   Drug: Fluorouracil;   Drug: Doxorubicin;   Drug: Streptozocin;   Drug: Dexamethasone;   Drug: Ondansetron
27 Recruiting RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Conditions: Carcinoma;   Neuroendocrine;   Non Functioning Neuroendocrine Tumors/NET;   Non Syndromic Neuroendocrine Tumors/NET;   Carcinoids;   Non Functioning
Intervention: Drug: Everolimus
28 Completed A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Condition: Neoplasms
Interventions: Drug: bevacizumab [Avastin];   Drug: 5 FU;   Drug: Streptozotocin;   Drug: Xeloda
29 Completed Evaluation of Blood Vessel Formation in Endocrine Tumors
Condition: Lesions
Intervention:
30 Enrolling by invitation Genetic Evaluation of Families With Endocrine Cancers
Conditions: Pancreatic Cancer;   Thymic Cancer;   Parathyroid Disease;   MEN1 Syndrome
Intervention: Genetic: Blood draw
31 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
Conditions: Muscle Rigidity;   Spasm;   Stiff Man Syndrome
Intervention: Drug: IVIg
32 Completed Vancomycin Associated Red Man Syndrome (RMS)
Condition: Red Man Syndrome
Intervention:
33 Recruiting Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
Condition: Stage IV Pancreatic Cancer
Intervention: Drug: Ascorbic Acid
34 Recruiting ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
Condition: Medullary Thyroid Carcinoma
Intervention: Drug: • TF2 and 68 Ga-IMP-288
35 Unknown  Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
36 Active, not recruiting BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Condition: Advanced Pancreatic Neuroendocrine Tumors (pNET)
Intervention: Drug: BEZ235
37 Unknown  Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter
Conditions: Pancreatic Neoplasms;   Cholangiocarcinoma;   Pancreatitis
Intervention: Device: Tissue sampling ("G.I.U.M." catheter)
38 Recruiting Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System
Condition: Unresectable Pancreatic Cancer
Intervention: Device: NanoKnife IRE System
39 Recruiting A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: MEK162, MEK inhibitor; oral;   Drug: Paclitaxel, mitotic inhibitor; intravenous
40 Completed Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Healthy Volunteers
Intervention: Drug: Tc 99m EC20

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years